Trial record 7 of 33 for:    LEAP

Promoting Tolerance to Peanut in High-Risk Children (LEAP)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Immune Tolerance Network (ITN)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00329784
First received: May 23, 2006
Last updated: April 4, 2012
Last verified: April 2012
  Purpose

This study will evaluate whether early exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema.


Condition Intervention
Peanut Allergy
Eczema
Egg Allergy
Food Allergy
Dietary Supplement: Age appropriate peanut snack
Behavioral: Peanut avoidance

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Proportion of participants with peanut allergy at 60 months of age [ Time Frame: 60 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Effect of peanut consumption or avoidance on other allergy outcomes [ Time Frame: 30 and 60 months ] [ Designated as safety issue: Yes ]
  • safety of peanut consumption among study participants [ Time Frame: 60 months ] [ Designated as safety issue: Yes ]
  • immunologic mechanisms by which consumption of a peanut-containing snack may induce tolerance to peanuts [ Time Frame: 60 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 640
Study Start Date: December 2006
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Peanut Consumption Group
Dietary Supplement: Age appropriate peanut snack
children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
Other Name: Bamba
Active Comparator: 2
Peanut Avoidance Group
Behavioral: Peanut avoidance
avoidance of peanut as per UK public health recommendations

Detailed Description:

Allergic reactions to peanuts are potentially life-threatening and, in some children, can result from ingestion of only trace quantities of peanuts. At highest risk are children with eczema or who are allergic to eggs; these children have a 20% chance of developing peanut allergy by the age of five. The majority of children allergic to peanuts have their first reaction between the ages of 14 and 24 months, often at the time of their first exposure to peanut. Currently, there is no cure for peanut allergy.

Peanut allergy has become an increasingly common problem in early childhood in the United States and the United Kingdom. Despite current public health guidelines in both countries recommending the avoidance of peanut consumption in the first years of life, the proportion of children with peanut allergy doubled in these countries over the period from 1998 to 2003. In contrast, peanuts are commonly consumed by infants in relatively high amounts in Africa, Southeast Asia and Israel, yet the rate of peanut allergy is quite low and does not appear to be increasing. Peanut consumption by infants in these parts of the world may actually protect children from developing peanut allergy by promoting oral tolerance to peanuts.

Participants in this study will be randomly assigned to either follow a peanut consumption regimen or a strict peanut avoidance regimen. Those assigned to the peanut consumption group will be asked to consume an age-appropriate snack three times a week for the duration of the study and will be monitored closely during their first introduction to peanut.

Those assigned to the peanut avoidance group will be asked to avoid ingestion of peanut for the first three years of life. A physical exam, allergy testing, and other immune system tests requiring blood collection will occur at Years 1, 3, and 5 following study entry. During the study, parents will maintain regular contact with study dietitians.

  Eligibility

Ages Eligible for Study:   4 Months to 10 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Allergy to eggs and/or severe eczema
  • Live within traveling distance to London, England, United Kingdom

Exclusion Criteria:

  • Clinically significant chronic illness. Participants with eczema or recurrent wheeze are not excluded.
  • Positive skin prick test for peanut allergen with a wheel diameter greater than 4 mm in the presence of a negative saline control
  • Previous or current consumption of peanut
  • Previous allergic reaction to peanut
  • Has sibling or primary caregiver who is allergic to peanut
  • Certain other immunologic criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00329784

Locations
United Kingdom
Evelina Children's Hospital, Guy's & St Thomas' NHS Foundation Trust
London, England, United Kingdom, SE1 7EH
Sponsors and Collaborators
Immune Tolerance Network (ITN)
Investigators
Principal Investigator: Gideon Lack, MD Imperial College, St. Mary's Hospital
  More Information

Additional Information:
Publications:
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00329784     History of Changes
Other Study ID Numbers: DAIT ITN032AD
Study First Received: May 23, 2006
Last Updated: April 4, 2012
Health Authority: United States: Federal Government
United Kingdom: National Health Service
United Kingdom: Research Ethics Committee

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
peanut allergy
egg allergy
eczema
peanut
allergy
allergies
allergic reaction
anaphylaxis
infants
children

Additional relevant MeSH terms:
Hypersensitivity
Eczema
Food Hypersensitivity
Egg Hypersensitivity
Peanut Hypersensitivity
Immune System Diseases
Dermatitis
Skin Diseases
Skin Diseases, Eczematous
Hypersensitivity, Immediate

ClinicalTrials.gov processed this record on April 20, 2014